{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:51:00Z","timestamp":1782449460811,"version":"3.54.5"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bilateral breast cancer is uncommon, accounting for 2%\u20135% of cases, and presents additional clinical challenges when tumors exhibit discordant molecular subtypes. Metachronous tumors, occurring sequentially, require individualized therapeutic strategies, especially when one tumor is triple-negative and the other is hormone-responsive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report on a 37-year-old woman who initially presented with a left-sided breast lump during her fifth pregnancy. Histopathology revealed invasive carcinoma of no special type (NST), progesterone receptor (PR)-positive (90%), estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2)-negative, with a high proliferative index (Ki-67\u00a0=\u00a090%), staged T2N2M0 (stage IIB\/IIIA). Subsequently, she developed a right-sided breast mass, confirmed as triple-negative invasive carcinoma (T4N3M0, stage IIIC). The patient was initiated on neoadjuvant chemotherapy with the adriamycin and cyclophosphamide (AC) regimen and received supportive care, including ondansetron, morphine, and bisacodyl. Her Eastern Cooperative Oncology Group (ECOG) performance status was 1, and she experienced significant weight loss (from 68 to 46\u00a0kg in 4 months). Post-chemotherapy imaging will guide surgical planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case highlights the rarity and complexity of metachronous bilateral breast cancer with discordant receptor status. Therapeutic prioritization is guided by the more aggressive tumor, in this instance, the triple-negative carcinoma, while simultaneously addressing the hormone-responsive lesion. Neoadjuvant chemotherapy allows tumor downstaging, assessment of chemosensitivity, and individualized surgical planning. Multidisciplinary management is essential to optimize outcomes and address prognostic variability between tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Metachronous bilateral breast cancer with discordant molecular subtypes presents significant diagnostic and management challenges. Individualized, biology-driven treatment strategies are critical, emphasizing the importance of systemic therapy guided by the more aggressive tumor and careful post-chemotherapy surgical planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1813996","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:36:36Z","timestamp":1782448596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Management challenges in metachronous bilateral breast cancer with discordant receptor status: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Aime","family":"Ishimwe Mugisha","sequence":"first","affiliation":[{"name":"College of Medicine and Health Sciences, School of Medicine and Pharmacy, University of Rwanda","place":["Kigali, Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert Denis","family":"Umuhizi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Butaro Level 2 Teaching Hospital","place":["Kigali, Rwanda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Olwit","sequence":"additional","affiliation":[{"name":"Internal Medicine, Kabale University School of Medicine","place":["Kabale, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"JCO"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2015.16.3.1007","article-title":"Impact of bilateral breast cancer on prognosis: synchronous versus metachronous tumors","volume":"16","author":"Ibrahim","year":"2015","journal-title":"Asian Pacific J Cancer Prev"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3390\/medicina61061029","article-title":"Illuminating bilateral breast cancer: a multicenter experience and clinical observations","volume":"61","author":"Karabu\u011fa","year":"2025","journal-title":"Medicina"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","unstructured":"Breast Cancer - Guidelines Detail"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/ijbc\/9082803","article-title":"Bilateral primary breast cancer with discordance in molecular subtypes: a case report","volume":"2025","author":"Rao","year":"2025","journal-title":"Int J Breast Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2019.07.008","article-title":"Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes","volume":"92","author":"Mruthyunjayappa","year":"2019","journal-title":"Hum Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"Von Minckwitz","year":"2012","journal-title":"JCO"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1813996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:36:53Z","timestamp":1782448613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1813996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":13,"alternative-id":["10.3389\/fonc.2026.1813996"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1813996","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1813996"}}